CS-2606 mRNA Multi-valent Influenza Vaccine
Influenza Prevention
Pre-clinicalActive
Key Facts
About CanSino Biologics
A leading Chinese vaccine developer leveraging adenovirus vector technology to create innovative vaccines for global infectious disease prevention.
View full company profileTherapeutic Areas
Other Influenza Prevention Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA-based Broad Flu Vaccine | Micron Biomedical | Pre-clinical |
| CaPtivaX Nasal Influenza Vaccine | CaPtivate Pharmaceuticals | Pre-clinical |
| Next-Generation Influenza Vaccines | Fluart Innovative Vaccines | Not Disclosed |
| HD-MAP Influenza Vaccine | Vaxxas | Phase 2/3 |
| IRT Platform (e.g., Influenza) | Biological Mimetics | Research/Pre-clinical |
| Replicon RNA Influenza Vaccine | BIKEN Group | Preclinical/Development |
| Innovative Influenza Vaccine | Livzon Pharmaceutical | Phase 1 |